**Figure 2. Alternative pathway of complement in AAV [40-50]**

**Alternative pathway**

- Factor B
  - Glomerular and urine levels of Bb associated with activity [48]

- C3b
  - C3F variant more frequent in AAV in candidate gene studies [43-45]
  - Further activation of complement by neutrophils (feedback loop)

- C5 convertase
  - C5a + C5b
  - Eculizumab

- Increased plasma levels of activated components C3a, C5a, Bb in AAV [49]

**Downstream effects**
- Degranulation
- Oxidative burst
- Enhanced phagocytosis
- Neutrophil chemoattractant